Why did Paul Herendeen resign as CFO?

Paul Herendeen resigned to accept a Chief Financial Officer position at another public company.

What is Glenn David's background and experience relevant to his new CFO role?

Glenn David has over 20 years of experience in finance and operations. He has been with Zoetis since its 2013 IPO, playing a key role in financial operations. He previously served as Senior Vice President of Finance Operations and also acted as interim CFO for Zoetis from April to August 2014. Before Zoetis, he held various financial roles at Pfizer, including with Pfizer Animal Health.

What is the compensation package for the new CFO, Glenn David?

Mr. David will receive an annual base salary of $585,000. He is eligible for an Annual Incentive Plan with a target incentive of 70% of his base salary. He will also receive a long-term incentive award for 2016 with a target of $1,100,000 and a sign-on Long Term Incentive Award valued at $550,000, consisting of stock options and restricted stock units vesting on the third anniversary of the grant date.

Are there any unusual arrangements related to Mr. David's appointment?

No, the filing states there are no arrangements or understandings with other persons for his appointment, no family relationships with directors or officers, and no transactions requiring disclosure under Item 404(a) of Regulation S-K. He will enter into the company's standard form of indemnification agreement.

ZTS 8-K: Leadership Changes

Summary

Zoetis Inc. announced a significant leadership change in its financial department with the appointment of Glenn David as the new Executive Vice President and Chief Financial Officer (CFO), effective immediately. Mr. David succeeds Paul Herendeen, who departed to take a CFO role at another public company. This transition brings in an executive with extensive experience within Zoetis and its predecessor, Pfizer Animal Health, underscoring a focus on internal talent and continuity in financial management. Mr. David's compensation package has been detailed, including a base salary, annual incentive plan, and a substantial long-term incentive award comprising stock options and restricted stock units. Investors can interpret this as a move to retain and incentivize key financial leadership, aiming to ensure stability and strategic financial oversight as the company continues its operations. The company also noted standard practices such as an indemnification agreement and eligibility for executive severance and U.S. benefits programs.

Key Highlights

1Glenn David appointed as new Executive Vice President and Chief Financial Officer (CFO) effective August 21, 2016.
2Paul Herendeen resigned as CFO to accept a CFO position at another public company.
3Mr. David brings over 20 years of finance and operations experience, including significant roles at Zoetis since its IPO and prior at Pfizer Animal Health.
4Mr. David previously served as acting CFO for Zoetis from April to August 2014.
5His compensation package includes an annual base salary of $585,000.
6Mr. David is eligible for annual incentives (target 70% of base salary) and long-term incentives totaling $1,100,000 for 2016, plus a $550,000 sign-on LTI award.
7A standard form of indemnification agreement will be entered into with Mr. David.

Zoetis Inc. 8-K Report, Executive Changes (Aug 22, 2016)

Summary

Key Highlights

Frequently Asked Questions